Lamevudine

Lamevudine is an antiviral.¹ It selectively inhibits wild-type hepatitis C virus (HCV) non-structural protein 5BΔ55 (NS5BΔ55) over NS5BΔ55 harboring a serine-to-threonine substitution at residue 282 (NS5BΔ55^S282T; IC₅₀s = 0.07 and 25 µM, respectively). Lamevudine selectively inhibits replication of HCV replicons in wild-type HBI10A cells over HBI10A cells expressing NS5BΔ55^S282T (EC₅₀s = 0.3 and 10.1 µM, respectively). In vitro, it reduces the cytopathic effect of positive-strand RNA viruses in the families Flaviviridae (EC₅₀s = 0.3-15 µM) and Picornaviridae (EC₅₀s = 0.5-5.9 µM) but not viruses of the negative-strand RNA virus family Paramyxoviridae. It inhibits the cytopathic effect and reduces virus yields of the Zika virus strain MR766 in infected Vero cells (EC₅₀s = 20 and 9.6 µM, respectively).² It also reduces serum viral load and delays virus-induced morbidity and mortality in AG129 mice, which lack Ifn-α/β and Ifn-γ receptors, infected with Zika virus when administered at a dose of 50 mg/kg per day.

WARNING This product is not for human or veterinary use.

1. Olsen, D.B., Eldrup, A.B., Bartholomew, L., et al. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob. Agents Chemother. 48(10), 3944-3953 (2004).

2. Zmurko, J., Marques, R.E., Schols, D., et al. The viral polymerase inhibitor 7-deaza-2'-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl. Trop. Dis. 10(5), e0004695 (2016).